{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:54:56Z","timestamp":1791042896567,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,11,18]],"date-time":"2010-11-18T00:00:00Z","timestamp":1290038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Defects in the DNA damage response pathway [e.g. del(17p)] are associated with drug\u2010resistant B\u2010cell chronic lymphocytic leukaemia (CLL). We previously demonstrated that over\u2010expression of DNA\u2010dependent protein kinase (DNA\u2010PK) correlates with chemo\u2010resistance and that inhibition of DNA\u2010PK sensitizes CLL cells to chemotherapeutics. Here, we investigated expression of DNA\u2010PK and other proteins that impact on drug resistance, and evaluated the effects of a DNA\u2010PK inhibitor (NU7441) on mitoxantrone\u2010induced cytotoxicity in CLL cells. NU7441 sensitized cells from 42\/49 CLL samples to mitoxantrone, with sensitization ranging from 2\u2010 to 200\u2010fold Co\u2010culture of CLL cells in conditioned stromal medium increased chemoresistance but did not reduce sensitization by NU7441. Mitoxantrone treatment induced \u03b3H2AX foci and NU7441 increased their longevity (24\u2003h). NU7441 prevented mitoxantrone\u2010induced autophosphorylation of the DNA\u2010PK catalytic subunit (DNA\u2010PKcs) at Ser 2056, confirming that DNA\u2010PK participates in repair of mitoxantrone\u2010induced DNA damage. del(17p) cases were more resistant to mitoxantrone than del(13q) cases, but were resensitized (7\u201316\u2003fold) by co\u2010incubation with NU7441. Expression of DNA\u2010PKcs, Ku80, P\u2010glycoprotein and topoisomerase II\u03b2 were significantly higher in del(17p) cases. <jats:italic>PRKDC<\/jats:italic> mRNA levels correlated with DNA\u2010PKcs protein expression, which predicted shorter survival. These data confirm the potential of DNA\u2010PK as a therapeutic target in poor prognosis CLL.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08425.x","type":"journal-article","created":{"date-parts":[[2010,11,18]],"date-time":"2010-11-18T06:06:20Z","timestamp":1290060380000},"page":"61-71","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Mitoxantrone in combination with an inhibitor of DNA\u2010dependent protein kinase: a potential therapy for high risk B\u2010cell chronic lymphocytic leukaemia"],"prefix":"10.1111","volume":"152","author":[{"given":"Sarah L.","family":"Elliott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Summerfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tryfonia","family":"Mainou\u2010Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Bedwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara W.","family":"Durkacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Willmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.04.099"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.118356"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4516"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(94)90190-2"},{"issue":"3","key":"e_1_2_7_6_1","first-page":"S39","article-title":"Expression of MDR1, MRP, topoisomerase IIalpha\/beta, and cyclin A gene expression in acute and chronic leukemias","volume":"10","author":"Beck J.","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00520.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1371"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.0442"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M408827200"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.09.029"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2888"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1124\/mol.56.6.1309","article-title":"Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation","volume":"56","author":"Errington F.","year":"1999","journal-title":"Molecular Pharmacology"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050444b"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.1114"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-233718"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2382"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600881421"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkm339"},{"key":"e_1_2_7_20_1","first-page":"1944","article-title":"Drug resistance mechanisms in chronic lymphocytic leukemia","volume":"10","author":"Ribrag V.","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404863"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2008.03.005"},{"key":"e_1_2_7_23_1","first-page":"781","article-title":"Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial","volume":"112","author":"Stilgenbauer S.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M803936200"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200608077"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120002156"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2527"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5158"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154070"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4275"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08425.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08425.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:04:39Z","timestamp":1697425479000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08425.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,18]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08425.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08425.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,18]]},"assertion":[{"value":"2010-11-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}